- Supported exchanges /
- F /
- 69O.F
AELIS FARMA SAS EO -004 (69O F) stock market data APIs
Aelis Farma SA, a clinical-stage biotechnology company, focuses on discovering and developing drug candidates for the treatment of central nervous system disorders. It is developing signaling-specific inhibitors of the CB1 receptors, such as AEF0117, a drug candidate, which is in Phase 2b clinical trials for the treatment of the harmful effects of excessive cannabis use; and AEF0217, a drug candidate, which is in phase I/II clinical trials to treat cognitive deficits observed in Down syndrome, as well as other cognitive impairments. The company was incorporated in 2013 and is headquartered in Bordeaux, France.
AELIS FARMA SAS EO -004 Financial Data Overview
| 3.38 | |
| 3.38 | |
| - | |
| 3.38 | |
| 3.38 | |
| 3.38-13.55 | |
| 47 401 K | |
| 13 618 K | |
| 10 781 K | |
| 0.086 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
AELIS FARMA SAS EO -004 Fundamental Data is available in our Financial Data APIs
- Net Revenue 10 781 K
- EBITDA -7 554 000
- Earnings Per Share -0.53
- Income Statements
- Balance Sheets
- Cash flows
of Fundamental API Data
Get AELIS FARMA SAS EO -004 Earnings via APIs
- Latest Release NaN
- EPS/Forecast NaN
Get AELIS FARMA SAS EO -004 End-of-day Data via APIs
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
